Literature DB >> 8078367

Overview of community-acquired pneumonia. Prognosis and clinical features.

G D Campbell1.   

Abstract

Despite the introduction of newer antibiotics, vaccinations, and better supportive care, CAP remains a common, frequently fatal disease. Age and coexisting illness influence which infectious agents are most likely to cause infection. Severity of illness and clinical features are influenced by various host factors and by the virulence of the infectious agent. Mortality and morbidity are reduced by the rapid institution of appropriate antimicrobial therapy. Because of the limitations of presently available diagnostic tests, many patients are begun on empiric regimens, and in up to half of these individuals, a cause is not identified. Although there are a number of potential pathogens, it is possible to identify likely pathogens based on easily identifiable clinical factors (age, presence of coexisting disease, severity of illness at presentation, and the need for hospitalization). Using this approach, CAP in immunocompetent adults may be divided into four categories. Once empiric therapy has been initiated, therapy should be continued for at least 72 hours unless clinical deterioration is noted. Within 4 days, fever and leukocytosis should return to baseline, but abnormal physical findings (i.e., crackles) require longer to resolve, especially with coexisting illness, and chest radiographic findings are the last to return to baseline and are especially delayed if the patient is bacteremic or has structural lung disease. Not all patients respond to initial empiric therapy. Reasons for this include antimicrobial resistance, the presence of nonbacterial pathogens (respiratory viruses), unusual bacterial pathogens, noninfectious causes that may mimic CAP, infectious complications (i.e., empyema), and pneumonia occurring in patients with unrecognized severe immunosuppression. Failure to improve after 72 hours and development of deterioration are indications for repeat diagnostic workup and consideration of alternative diagnoses. More invasive diagnostic tests are appropriate in severely ill patients and in those whose condition is deteriorating rapidly.

Entities:  

Mesh:

Year:  1994        PMID: 8078367     DOI: 10.1016/s0025-7125(16)30118-3

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  10 in total

1.  Soluble triggering receptor expressed on myeloid cells in sputum of patients with community-acquired pneumonia or pulmonary tuberculosis: a pilot study.

Authors:  G R Tintinger; J J van der Merwe; H Fickl; P Rheeder; C Feldman; R Anderson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-05-11       Impact factor: 3.267

2.  Intrapulmonary delivery of tumor necrosis factor agonist peptide augments host defense in murine gram-negative bacterial pneumonia.

Authors:  L L Laichalk; K A Bucknell; G B Huffnagle; J M Wilkowski; T A Moore; R J Romanelli; T J Standiford
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

3.  Delay in appropriate therapy of Legionella pneumonia associated with increased mortality.

Authors:  C H Heath; D I Grove; D F Looke
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-04       Impact factor: 3.267

4.  A predictive model for the treatment approach to community-acquired pneumonia in patients needing ICU admission.

Authors:  P M Olaechea; J M Quintana; M S Gallardo; J Insausti; E Maraví; B Alvarez
Journal:  Intensive Care Med       Date:  1996-12       Impact factor: 17.440

5.  Nitric oxide is required for effective innate immunity against Klebsiella pneumoniae.

Authors:  W C Tsai; R M Strieter; D A Zisman; J M Wilkowski; K A Bucknell; G H Chen; T J Standiford
Journal:  Infect Immun       Date:  1997-05       Impact factor: 3.441

6.  Disease burden of community acquired pneumonia among children under 5 y old in China: A population based survey.

Authors:  Yan Li; Zhijie An; Dapeng Yin; Yanmin Liu; Zhuoying Huang; Yujie Ma; Hui Li; Qi Li; Huaqing Wang
Journal:  Hum Vaccin Immunother       Date:  2017-04-17       Impact factor: 3.452

7.  Tumor necrosis factor mediates lung antibacterial host defense in murine Klebsiella pneumonia.

Authors:  L L Laichalk; S L Kunkel; R M Strieter; J M Danforth; M B Bailie; T J Standiford
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

8.  Can we predict which patients with community-acquired pneumonia are likely to have positive blood cultures?

Authors:  Samuel George Campbell; R Andrew McIvor; Vincent Joanis; David Graydon Urquhart
Journal:  World J Emerg Med       Date:  2011

Review 9.  [Managing lower respiratory tract infections in immunocompetent patients. Definitions, epidemiology, and diagnostic features].

Authors:  F Philippart
Journal:  Med Mal Infect       Date:  2006-11-07       Impact factor: 2.152

10.  Predictors of cardiogenic and non-cardiogenic causes in cases with bilateral chest infiltrates.

Authors:  Yeon Joo Lee; Jinwoo Lee; Young Sik Park; Sang-Min Lee; Jae-Joon Yim; Chul-Gyu Yoo; Young Whan Kim; Sung Koo Han; Chang-Hoon Lee
Journal:  Tuberc Respir Dis (Seoul)       Date:  2013-01-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.